INTRODUCTION {#sec1}
============

Prokaryotes often carry multiple immune systems (Labrie, Samson and Moineau [@bib26]; Doron *et al*. [@bib16]), including a highly sophisticated adaptive immune system known as CRISPR-Cas (Clustered Regularly Interspaced Short Palindromic Repeats---CRISPR-associated), reviewed in (Marraffini [@bib33]). This system functions by integrating sequences of viruses, plasmids and transposable elements (Barrangou *et al*. [@bib3]; Bikard *et al*. [@bib4]; Lopez-Sanchez *et al*. [@bib31]) (known as spacers) into CRISPR loci, which subsequently provide immunity against re-infection (Barrangou*, et al*. [@bib3]; Brouns *et al*., [@bib9]; Tyson and Banfield, [@bib43]; Datsenko *et al*. [@bib14]; Swarts *et al*. [@bib41]; Yosef, Goren and Qimron [@bib53]; van Houte, Buckling and Westra [@bib45]). Conjugative plasmids often carry antibiotic resistance genes and therefore play a crucial role in the spread of antibiotic resistance (Maiden [@bib32]; Dionisio *et al*. [@bib15]; Svara and Rankin, [@bib40]; Carattoli, [@bib11]). Whether CRISPR-dependent immunity to plasmids is important in limiting the spread of antibiotic resistance (Marraffini and Sontheimer, [@bib34] and Palmer and Gilmore, [@bib36]; Gophna *et al*. [@bib19]) depends on the efficacy of the CRISPR-Cas immune system (Hullahalli *et al*. [@bib21]), and on the fitness cost associated with carrying the plasmid (in the absence of antibiotics) and the cost of resistance associated with CRISPR-immunity. Experimental observations (Jiang *et al*. [@bib24]; Vercoe *et al*. [@bib47]) and theory predicts that CRISPR-Cas systems can degenerate if they carry a cost (Levin [@bib28]; Weinberger, Wolf and Lobkovsky [@bib48]; Iranzo *et al*. [@bib22]). While large costs are likely when the CRISPR-Cas system behaves maladaptively, such as autoimmunity (Stern *et al*. [@bib39]; Vercoe *et al*. [@bib47]) and the prevention of beneficial infection (Bikard *et al*. [@bib4]; Jiang *et al*. [@bib24]), there may also be costs when the system prevents infection by costly genetic elements, for example due to immunopathological effects or energetic costs of immune activation (Vale *et al*. [@bib44]; Westra *et al*. [@bib51]; Westra *et al*. [@bib49]; van Houte *et al*. [@bib46]). Here, we investigate this possibility using *Escherichia coli* and the conjugative F-plasmid pOX38-Cm. Our data show that CRISPR-mediated immunity against this costly plasmid is associated with a fitness cost under non-selective conditions. Our data further suggest that this cost of immunity may not only result from energetic costs, but is caused by a plasmid-encoded CcdAB toxin--antitoxin (TA) addiction system (Ogura and Hiraga [@bib35]; Jaffe, Ogura and Hiraga [@bib23]; Bahl, Hansen and Sorensen [@bib2]), which plays a critical role in avoiding plasmid curing (Hayes [@bib20]). Hence, TA systems may limit the evolution of bacterial adaptive immunity against plasmids, which could have important consequences for the spread of antibiotic resistance.

METHODS {#sec2}
=======

Bacterial strains {#sec2-1}
-----------------

*Escherichia coli* K12 Δ*hns* (BW25113) strains, which have a constitutively active CRISPR-Cas system (Pul *et al*. [@bib37]; Westra *et al*. [@bib52]) were used as recipient cells. These strains, which were obtained from the KEIO collection, were cured from the kanamycin resistance cassette using FLP recombinase (Datsenko and Wanner [@bib13]) and were engineered to carry synthetic CRISPR loci, sequences of which can be found in [Table S2](#sup1){ref-type="supplementary-material"} ([Supporting Information](#sup1){ref-type="supplementary-material"}). *Escherichiacoli* MC4100 carrying pOX38-Cm was used as the donor strain.

Cloning of spacers, lacZ and CcdA {#sec2-2}
---------------------------------

Spacers, *lacZ* and *ccdA* were cloned into the recombination cassette located on the previously described plasmid pRECOMB-Cr2.1(Westra *et al*. [@bib52]). Spacer-containing DNA fragments from plasmid pWUR693 and pWUR700 (Westra *et al*. [@bib50]) were cloned using the BamHI and EcoRI restriction sites of pRECOMB-Cr2.1. The *lacZ* and *ccdA* genes were PCR amplified from the *E. coli* K12 W3110 genome and plasmid pOX38-Cm, respectively ([Figure S1, Tables S1 and S2, Supplementary Information](#sup1){ref-type="supplementary-material"}) and cloned using restriction enzymes NotI and KpnI. Resulting plasmids were used as a template for PCR amplification using primers BG4452 and BG4453 ([Figure S1, Tables S1 and S2, Supplementary Information](#sup1){ref-type="supplementary-material"}) and the amplicon was subsequently gel purified. *Escherichia coli* Δ*hns* cells containing the plasmid pKD46 were transformed with the amplicon (Datsenko and Wanner [@bib13]), after which the bacteria were plated on LB agar containing kanamycin (50 mg/L) to select for recombinants. Plated bacteria were grown at 37°C overnight to cure the cells from pKD46. Recombination was confirmed using colony PCR and Sanger sequencing (GATC Biotech, Germany).

Growth measurements {#sec2-3}
-------------------

Growth curves of *E. coli* K12 Δ*hns* (BW25113) and *E. coli* K12 Δ*hns* (BW25113) carrying pOX38-Cm were measured as follows. Bacteria were inoculated 1:100 in 1 L fresh LB medium from overnight cultures containing the same optical density and grown at 37°C while shaking at 180 rpm (four replicas per treatment). The optical density (OD~600~) of the cultures was measured every 30 min. At each of these time points a sample of 10 or 20 mL was taken. Cells were washed with Millipore water and dried overnight at 130°C. The dry weight of the bacteria was measured of every sample to determine the specific growth rate (in gram new cells·gram cell^−1^·hr^−1^). The specific growth rate was determined for the log phase of the growth curve and used as a measurement of bacterial fitness.

Competition experiments {#sec2-4}
-----------------------

Competition experiments were inoculated from overnight cultures grown at 37°C with equal optical densities. Competition experiments were performed in microcosms (6 mL LB medium in 30 mL glass vials, 6 replicas per treatment), containing 60 μL of every culture used in the experiment. Competition experiments were incubated at 37°C at 100 rpm and a daily transfer of 120 μL of the competition experiments into fresh microcosms was carried out. After 2 days cells were plated on LB agar containing kanamycin (50 mg/L) and X-gal (50 mg/L). Colony counting of blue and white colonies was used to determine relative fitness of CRISPR-immune (white colonies) and CRISPR-sensitive strains (blue colonies). Experiments were performed in presence or absence of pOX38-Cm to measure the effect of plasmid presence on the fitness of the bacterial strains. Statistical analysis was performed using JMP10 Software.

RESULTS {#sec3}
=======

It has previously been shown that the Type I-E CRISPR-Cas adaptive immune system of *E. coli* (Fig. [1A](#fig1){ref-type="fig"}) can effectively protect against conjugative transfer of plasmid pOX38-Cm (Westra *et al*. [@bib50]), which is a derivative of the well-studied plasmid F and encodes chloramphenicol (Cm) resistance. Measurements of the specific growth rates of *E. coli* Δ*hns* reveal that carrying plasmid pOX38-Cm reduces growth rates with 27% when antibiotics are absent (Fig. [1B](#fig1){ref-type="fig"} and Table [1](#tbl1){ref-type="table"}; F~1,7~ = 50.67, *P* = 0.0004). Based on the difference in growth rate between plasmid-containing and plasmid-free cells in monoculture, CRISPR-mediated immunity against the plasmid would be expected to result in a large fitness benefit. To measure the relative fitness associated with CRISPR immunity, competition experiments were performed between CRISPR-immune and susceptible *E. coli* K12 derived strains. To this end, the genome of *E. coli* K12 Δ*hns* was engineered to replace the CRISPR 2.1 locus flanking the *cas* genes with synthetic CRISPR arrays that either target (strain T) plasmid pOX38-Cm or that do not target (non-targeting; strain NT) the plasmid (Fig. [1A](#fig1){ref-type="fig"}). After competing strain T and strain NT for two days the resulting relative fitness is approximately one, indicating that the two strains have comparable fitness (Fig. [1C](#fig1){ref-type="fig"}; 1-sample t-test, T~5 ~= 1.19, *P* = 0.29). Surprisingly, the presence of a donor strain that carries conjugative plasmid pOX38-Cm did not cause a significant fitness increase of the T strain compared to when the plasmid was absent (Fig. [1C](#fig1){ref-type="fig"}; F~1,11~ = 4.23, *P* = 0.067). These data therefore suggest that the cost of immunity is of the same order of magnitude as the cost of carrying the plasmid.

![**(A)**, Overview of the engineered CRISPR locus of the T strain (targeting pOX38-Cm), the NT strain (not targeting pOX38-Cm, encoding LacZ) and the T*ccdA* strain (targeting pOX38-Cm, encoding CcdA). Genes are indicated by arrows. The CRISPR locus consists of repeats (black) and spacers (white). The spacer targeting pOX38-Cm is indicated by horizontal stripes. **(B)**, Optical densities at 600 nm (OD~600~) of plasmid-free (Δ*hns*) cells and plasmid-containing (Δ*hns + *pOX38-Cm) cells at different time points after inoculation. Measurements of dry weight were used to determine specific growth rates (g new cells·g cells^−1^·hr^−1^, Table [1](#tbl1){ref-type="table"}). **(C)**, Relative fitness (mean ± 95% CI) of T strain in the absence or presence of the pOX38-Cm donor strain after 2 days of competition with NT strain. **(D)**, Relative fitness (mean ± 95% CI) of T*ccdA* strain in the absence or presence of the pOX38-Cm donor strain after 2 days of competition with NT strain.](fnz047fig1){#fig1}

###### 

Specific growth rates of bacteria with and without plasmid pOX38-Cm.

  ------------------- ---------------------------------------------------------
  Strain              Specific growth rate (g new cells\*g cells^−1^\*hr^−1^)
  Δ*hns*              0.90 ± 0.06
  Δ*hns* + pOX38-Cm   0.66 ± 0.04
  ------------------- ---------------------------------------------------------

Given the T and NT strains did not differ in fitness in the absence of the plasmid, we hypothesized that the cost of immunity associated with CRISPR-Cas could be due to gene expression from the invading plasmid prior to detection by the immune system, analogous to the expression of anti-CRISPR genes from phage genomes prior to CRISPR-mediated cleavage of the phage genomes (Bondy-Denomy *et al*. [@bib5]; Borges *et al*. [@bib8]; Landsberger *et al*. [@bib27]). Although any of the plasmid genes could contribute to this cost, it is well documented that expression of plasmid-encoded addiction systems would be particularly harmful. Addiction systems prevent plasmid curing, since removal of the plasmid results in rapid depletion of the anti-toxin whereas the toxin will persist for longer periods of time to eventually cause cell death (Gerdes and Maisonneuve [@bib17]; Cook *et al*. [@bib12]). The toxin--anti-toxin (TA) system of plasmid pOX38-Cm is encoded by the *ccdAB* genes; the CcdB toxin is neutralized by the CcdA anti-toxin. In the absence of the short-lived CcdA anti-toxin the CcdB toxin inhibits DNA gyrase, which eventually leads to cell death (Cook *et al*. [@bib12]).

To test the hypothesis that this TA system contributes to the cost of resistance we engineered an *E. coli* strain to express the CcdA anti-toxin from the genome in addition to carrying the T CRISPR (T*ccdA* strain; Fig. [1A](#fig1){ref-type="fig"}). This strain is immune to plasmid pOX38-Cm and to the detrimental effect of toxin CcdB since the toxin is neutralized by CcdA. Competition between the T*ccdA* and the NT strain in the absence of the conjugative plasmid reveals that encoding CcdA on the genome is associated with a fitness cost (relative fitness = 0.37) (Fig. [1D](#fig1){ref-type="fig"}; T~5~ = −19.2, *P* \< 0.0001) after two days of competition. By contrast, when competing T*ccdA* and NT for two days in the presence of a donor strain that carries the pOX38-Cm plasmid, the T*ccdA* strain has a large fitness benefit (relative fitness = 15.2) (Fig. [1D](#fig1){ref-type="fig"}; T~5~ = 3.5, *P* = 0.017). Hence, these data demonstrate that expression of the anti-toxin from the bacterial chromosome alleviates the cost of CRISPR immunity, suggesting that TA expression from the plasmid prior to its degradation by CRISPR-Cas immune systems may be an important contributor to the observed cost of immunity.

DISCUSSION {#sec4}
==========

Costs of resistance potentially have profound effects on co-evolutionary dynamics (Agrawal and Lively [@bib1]; Lopez-Pascua and Buckling [@bib30];Gomez and Buckling [@bib18]; Buckling and Brockhurst [@bib10]) and are directly responsible for the existence of trade-offs between immunity and other life-history traits (Boots and Begon [@bib6]; Boots and Bowers [@bib7]; Little and Killick [@bib29]; Kempel *et al*. [@bib25]). Our data suggest that TA systems encoded by plasmids may cause CRISPR immunity against an invading plasmid to be costly, due to the time-lag between infection and clearance of the infection during which the TA system may already be expressed. As a result of this cost the CRISPR system may have little net benefit against costly plasmids if they encode TA-systems. This could explain the limited spread and degeneration of CRISPR-Cas systems, and may also help to explain observations of high degrees of susceptibility to costly plasmids in *E. coli* (Touchon *et al*. [@bib42]). Furthermore, many antibiotic resistance genes are carried on conjugative plasmids containing TA systems (Maiden [@bib32], Dionisio *et al*. [@bib15]; Svara and Rankin [@bib40]; Carattoli [@bib11]). As such, there will be relatively weak selection to resist these plasmids via CRISPR-Cas, even in the absence of antibiotic selection. Our findings also indicate that using CRISPR-Cas as a tool to resensitize bacteria to antibiotics by selectively removing antibiotic resistance-carrying conjugative plasmids (Pursey *et al*. [@bib38]) may be challenging when these plasmids encode TA systems.
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Click here for additional data file.
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